A Registry Study of Biomarkers in Mitral Valve Disease (BIOMS-MVD)

Beijing Institute of Heart, Lung and Blood Vessel Diseases5,000 enrolled

Overview

The registry study aims to discover the prognostic value of bio-markers in mitral valve disease

The purpose of this study is to investigate the prognostic value of biomarkers in mitral valve disease.Patients with confirmed diagnosis of mitral valve disease are enrolled.The primary outcome is all-cause mortality based on the death certificates. The secondary outcome is readmission for heart failure and all-cause mortality/readmission for heart failure according to the patients' medical records.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Cardiovascular Diseases

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients clinically diagnosed with mitral valve disease in Beijing Anzhen Hospital from April 2016 to December 2019 * The operator performs more than 25 mitral valve operations per year / the operator unit has surgeons who complete 50 operations per year Exclusion Criteria: * Age ≤ 18 years * Failure to obtain medical records and ultrasound data * Refuse follow-up

Locations (1)

Beijing Anzhen Hospital

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Number of death (all cause)

Number of death within 2 years of discharge

Time frame: 1 years of follow-up

Secondary Outcomes

Number of rehospitalizations

Number of heart failure related hospitalization within 1 years of discharge

Time frame: 1 years of follow-up

Central Contacts

Yuan Wang, Dr

CONTACT

13910161443 wangyuan980510@163.com

Ning Zhou, Dr

CONTACT

18611179515 drzhou9515@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.